Filing Details
- Accession Number:
- 0000899243-19-025638
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-10-16 20:36:59
- Reporting Period:
- 2019-10-14
- Accepted Time:
- 2019-10-16 20:36:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1285819 | Omeros Corp | OMER | Pharmaceutical Preparations (2834) | 911663741 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1472158 | J. Thomas Cable | C/O Omeros Corporation 201 Elliott Avenue West Seattle WA 98119 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2019-10-14 | 5,000 | $15.12 | 35,067 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Open market sale pursuant to a previously established Rule 10b5-1 trading plan adopted by the reporting person. The trading schedule, including sale periods and the number of shares to be sold, was determined at the time of the trading plan's adoption in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The reporting person's Rule 10b5-1 trading plan further provides for the exercise and sale of up to 10,000 shares underlying outstanding stock options that will expire in December 2019 and 5,000 shares underlying stock options that will expire in May 2020.
- This transaction was executed in multiple trades at prices ranging from $14.64 to $15.44; the price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide full information regarding the number of shares and prices at which the transactions referenced in this footnote were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.
Billionaire Hedge Funds
